Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 16Colorectal Neoplasms 9Liver Neoplasms 8Cholangiocarcinoma 8Recurrence 5Klatskin Tumor 4Neoplasm Metastasis 3Fibrosis 3Neoplasms 2Bile Duct Neoplasms 2Reperfusion Injury 1Rejection, Psychology 1Patient Dropouts 1PRETEXT I Hepatoblastoma 1Liver Diseases, Alcoholic 1Liver Diseases 1Hypertension, Portal 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Colorectal Liver Metastases 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangitis, Sclerosing 1Alcoholism 1

Interventions

Propranolol 3Portasystemic Shunt, Transjugular Intrahepatic 2tremelimumab 1durvalumab 1Radiofrequency Ablation 1Liver Transplantation 1Hepatectomy 1Diagnostic Imaging 1Carvedilol 1Bevacizumab 16-acetylaminocaproic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension, Portal × Liver Transplantation × Gastrointestinal × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡